Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
modified epigallocatechin gallate formulation
- Development stage
- Preclinical
- Lead developer
- Merdury Biopharmaceutical
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Modified epigallocatechin gallate (EGCG) formulation is an oral small molecule therapeutic developed by Merdury Biopharmaceutical for the treatment of Duchenne Muscular Dystrophy (DMD). The drug is produced using the proprietary StackDose platform, which utilizes 3D printing technology to create a formulation with optimized solubility and bioavailability. EGCG, a polyphenol naturally found in green tea, has demonstrated anti-inflammatory and anti-fibrotic properties in preclinical studies, suggesting potential to reduce muscle damage and improve motor function in DMD patients. The program was granted Orphan Drug Designation and Rare Pediatric Disease Designation by the US FDA in 2024 and is currently in preclinical development.
- Other names
- modified EGCG formulationDMD DrugJosin's Muscular Dystrophy DrugModified epigallocatechin gallate formulation
02
Targets
MMP12 (Macrophage Metalloelastase)PTGS2 (Prostaglandin-Endoperoxide Synthase 2)ABCB1 (P-glycoprotein)RPSA (37/67 kDa laminin receptor)EGFR (Epidermal growth factor receptor)CYP1A2 (Cytochrome P450 1A2)OATP1A2 (Solute carrier organic anion transporter family member 1A2)CYP3A4 (Cytochrome P450 3A4)HSP90AA1 (Heat shock protein HSP90-alpha)
Beyond the preview
Go deeper on modified epigallocatechin gallate formulation.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on modified epigallocatechin gallate formulation.